A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab, or With Standard of Care Chemotherapy, Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer
收藏DataCite Commons2025-12-12 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012128/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to determine whether an investigational immunotherapy nivolumab in combination with ipilimumab or in combination with standard of care chemotherapy is more effective than standard of care chemotherapy alone in treating participants with previously untreated inoperable or metastatic urothelial cancer.
提供机构：
Vivli
创建时间：
2025-12-11
